View Full Version : Nuvilex Inc.

  1. All Eyes On Pharmacyte Biotech Inc (OTCMKTS:PMCB)
  2. FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment
  3. Nuvilex, Inc. (OTCMKTS:NVLX) Hesitates Around The 25 Cent Mark
  4. Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
  5. Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors
  6. Nuvilex (NVLX) Heads To The Clinic With An Opportunity To Treat A Wider Range Of Cancers
  7. Nuvilex (NVLX) CEO And COO Discuss Preclinical And Clinical Trials, Orphan Drug Status, Funding And Much More In Interview
  8. Nuvilex (NVLX) Now Has Access To $50 Million With New Banking Agreement
  9. Nuvilex (NVLX) To Present At The LD MICRO Invitational Conference On June 4, 2014
  10. Nuvilex (NVLX) Enters Into An At The Market Banking Agreement With Chardan Capital Markets
  11. Nuvilex (NVLX) And Translational Drug Development (TD2) Begin Preparations For US-Based Studies On Symptoms Associated With Pancreatic Cancer
  12. Nuvilex Signs Agreement To Study Development Of Cannabis-Based Cancer Treatments
  13. Nuvilex's Pancreatic Cancer Treatment Continues To Outperform Big Pharma Heading Into Late Phase Trials
  14. Nuvilex Adds World Renowned Oncologist And Gastroenterologist To Play Major Role In Late Phase Clinical Trial
  15. Nuvilex Applying For Orphan Drug Status To Market Pancreatic Cancer Treatment Without Competition
  16. Nuvilex Contracts With Clinical Network Services Pty Ltd For Late-Phase Clinical Trials In Pancreatic Cancer
  17. Nuvilex Engages ViruSure to Establish Cell Banks for Phase 2b Clinical Trials in Pancreatic Cancer
  18. Nuvilex Investors Should Read Between The Lines As Company Attracts World Renowned Oncologist
  19. Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer
  20. Nuvilex To Present At National Medical Cannabis Unity Conference In Washington DC
  21. Austrianova (Austria) Contracted By Nuvilex For cGMP-Compliant Cell-In-A-Box® Encapsulation Of Cells
  22. Form 10-Q for NUVILEX, INC.
  23. Pancreatic Cancer Trials presented at conference
  24. Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board
  25. Nuvilex Appoints Dr. Garret L. Yount to Its Subsidiary's Scientific Advisory Board
  26. Form 8-K on 6-Mar-2014
  27. Nuvilex Partner Austrianova Establishes Regional Headquarters And Research And Development Facility At Thailand Science Park For Cell-In-A-Box™ Live-Cell Encapsulation
  28. Nuvilex Funding Has Investors Preparing For Milestone Announcements In Late-Phase Clinical Trials
  29. Nuvilex Announces $27 Million Funding Commitment With Institutional Investor
  30. Nuvilex's Marijuana Research And Treatments Get Closer With Banking Discussions
  31. Nuvilex's Medical Marijuana Sciences Prepares to Enhance Industry's Research With Cell-in-a-Box™
  32. Nuvilex's Medical Marijuana Sciences Ready To Welcome New York State's Approval Of The Drug
  33. Nuvilex's Medical Marijuana Subsidiary Poised For Growth In The New Year
  34. Nuvilex Lands Leading Figure In Medical Marijuana Field As Chairman Of Subsidiary's Scientific Advisory Board
  35. Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology To Address Brain Cancers
  36. Nuvilex To Answer Increasing Calls For Better Pancreatic Cancer Treatment Without Gemcitabine
  37. Nuvilex Ahead Of The Curve On Cannabidiol As FDA Issues Landmark Approval
  38. Nuvilex Accelerates Development Of Treatments For Cancer And Diabetes With New Corporate Management Structure
  39. Nuvilex's Acquisition Of Diabetes Rights Should Put The Company On Everyone's Radar
  40. Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes
  41. Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
  42. Nuvilex Featured in Recent Forbes and New York Post Articles
  43. Nuvilex Enters Most Important Step of Phase III Trials Outside of Patient Enrollment
  44. Nuvilex Names Two Significant Partners on Its Way to Phase 3 Clinical Trials
  45. Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials
  46. Form 10-Q NUVILEX, INC. For: Jul 31
  47. Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer
  48. Nuvilex Investors Watch as Incyte Corporation (INCY) Shares Rise Sharply on Pancreatic Cancer Trials Data
  49. Nuvilex Investors Should Heed FINRA Warnings
  50. Nuvilex Remains Under Fire While Investors Hold
  51. Nuvilex Restructures Corporate Operations to Reflect Biotechnology Focus
  52. Drug Makers Could Soon Turn Away From Eli Lilly and Company (LLY)'s Gemzar and Toward Nuvilex's Cell Encapsulation
  53. Nuvilex's Medical Marijuana Segment Could Mirror Israel's Success
  54. Nuvilex, Inc. Moves Closer to Head to Head With Eli Lilly in Phase III Clinical Trials
  55. Nuvilex Acquisition Could be Steal of the Century and Worth Billions
  56. Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Pancreatic Cancer Treatment Technology
  57. Nuvilex Will Enter Phase III Trials With Advantages Using Cell Encapsulation
  58. Nuvilex, Johnson & Johnson (JNJ) and Medtronic, Inc. (MDT), All Developing Type of Artificial Pancreas for Diabetics
  59. Nuvilex's Phase III Pancreatic Cancer Trials Could Address New Law's Call for Progress
  60. Nuvilex's Cell Encapsulation Could Play Role in Multimodality Treatment of Cancer Patients
  61. Nuvilex's Dr. Gerald Crabtree Discusses Upcoming Phase III Cancer Trials, Fast Track and Orphan Drug Status
  62. Nuvilex Pancreatic Cancer Trials Could Make "Cell-in-a-Box" Gold Standard
  63. Nuvilex Price Valuation Justifies Investors' Confidence in Biotech
  64. Nuvilex Release: Human Clinical Trials Using Medical Marijuana Could be Close in the U.S.
  65. Nuvilex Expects its Technology Can Start to Change Life for Diabetics
  66. Nuvilex Phase III Clinical Trials in Strong Hands With Dr. Gerald Crabtree
  67. Potential Future Sales of Nuvilex Cancer Treatments Make Investment in Cell-in-a-Box Worth It
  68. Form 10-K International Stem Cell For: Dec 31
  69. Timing is Right for Big Pharma to Add Nuvilex Technology to Its Pipeline
  70. Nuvilex Focused on Positioning Subsidiary, Medical Marijuana Sciences, Inc., to be a Leading Medical Marijuana Entity by Developing Brain and Pancreatic Cancer Treatments
  71. chameleon
  72. Nuvilex COO Highlights Advantages and Applications of Platform Cell Encapsulation Technology for Cancer, Diabetes, and Stem Cells During Recent Interview With SmallSector.com
  73. Form 10-K NUVILEX, INC. For: Apr 30
  74. Nice bump up today!
  75. doubled up
  76. volume
  77. pancraetic cancer NVLX.
  78. Nuvilex Forecasts Vast Partnership Opportunities
  79. latest news
  80. good news!!
  81. like penny stocks?
  82. nvlx breaking out!!!
  83. Nuvilex Reveals Goldman Small Cap Research Cites Groundbreaking Cancer Therapy
  84. Nuvilex Reports Encapsulated Living Cells Technology for Pancreatic Cancer Treatment
  85. Nuvilex Announces Major Breakthrough for Live Stem Cell Use and Applications
  86. Nuvilex Highlights the Unique Aspects of the Encapsulation Technology with Live Stem Cells
  87. Nuvilex’s Affiliate Presents Cell in a Box(R) Technology in Seoul at BIO KOREA 2011
  88. Nuvilex Advances Studies Combining Its Encapsulation and Live Stem Cell Technologies
  89. Nuvilex’s SG Austria Affiliate to Present at Phacilitate Cell & Gene Therapy Forum Asia 2011
  90. Nuvilex’s Successes-Getting Noticed
  91. SG Austria acquisition benefits Nuvilex
  92. Nuvilex Reports Significant Interest in All Products
  93. Nuvilex Enters $21.5 Billion Stem Cell Arena

Content Relevant URLs by vBSEO 3.6.0 PL2